Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC)
Geissler, M., Tannapfel, A., Reinacher-Schick, A., Martens, U., Ricke, J., Riera-Knorrenschield, J., Kanzler, S., Held, S., Heinemann, V., Seufferlein, T., Modest, D.
Published in Annals of oncology (01.07.2019)
Published in Annals of oncology (01.07.2019)
Get full text
Journal Article
mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109)
Geissler, M., Klingler, T., Riera-Knorrenschield, J., Tannapfel, A., Seufferlein, T., Held, S., Florschütz, A., Kanzler, S., Heinemann, V., Reinacher-Schick, A., Martens, U.
Published in Annals of oncology (01.06.2018)
Published in Annals of oncology (01.06.2018)
Get full text
Journal Article
PD-030Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC)
Geissler, M, Tannapfel, A, Reinacher-Schick, A, Martens, U, Ricke, J, Riera-Knorrenschield, J, Kanzler, S, Held, S, Heinemann, V, Seufferlein, T, Modest, D
Published in Annals of oncology (01.07.2019)
Published in Annals of oncology (01.07.2019)
Get full text
Journal Article
O-024mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109)
Geissler, M, Klingler, T, Riera-Knorrenschield, J, Tannapfel, A, Seufferlein, T, Held, S, Florschütz, A, Kanzler, S, Heinemann, V, Reinacher-Schick, A, Martens, U
Published in Annals of oncology (01.06.2018)
Published in Annals of oncology (01.06.2018)
Get full text
Journal Article